World's Best Scientists 2026 revealed!
Philip Poortmans

Philip Poortmans

D-Index & Metrics

Medicine

D-Index
81
Citations
32250
World Ranking
16437
National Ranking
207

Philip Poortmans publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Philip Poortmans sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 459 publications — 51st percentile

51% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Philip Poortmans D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Philip Poortmans sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 81 D-Index — 19th percentile

19% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Philip Poortmans is affiliated with the University of Antwerp in Belgium and specializes in medical research focused on cancer, particularly breast cancer. Their scholarly contributions span a significant number of publications concentrated within medicine and biochemistry, genetics, and molecular biology.

Their research prominently involves studies related to breast cancer treatment, breast lesions and carcinomas, and breast implant and reconstruction. Other notable topics addressed in their work include global cancer incidence and screening, advanced radiotherapy techniques, oncology and radiotherapy advances, and cancer genomics and diagnostics.

Philip Poortmans has authored and co-authored several papers published in well-regarded journals. Some of the recent notable papers include:

  • "Breast cancer" (2021), published in The Lancet
  • "Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021" (2021), published in Annals of Oncology
  • "Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up" (2023), published in Annals of Oncology
  • "Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13,864 women in seven randomised trials" (2021), published in The Lancet Oncology
  • "Internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial" (2020), published in The Lancet Oncology

The publication history of Philip Poortmans includes frequent appearances in a range of specialized journals such as:

  • Radiotherapy and Oncology
  • The Breast
  • The Lancet Oncology
  • Annals of Oncology
  • International Journal of Radiation Oncology*Biology*Physics

Their collaborative work involves regular coauthors, many of whom have contributed extensively alongside them. Notable frequent coauthors are:

  • Orit Kaidar-Person
  • Icro Meattini
  • Liesbeth Boersma
  • Birgitte Vrou Offersen
  • Giuseppe Curigliano

Their main academic domain consolidates work in medicine with a comprehensive focus on oncology and cancer research, alongside specialties such as radiology, nuclear medicine, imaging, surgery, and pulmonary and respiratory medicine. This multidisciplinary approach facilitates contributions to both clinical practice guidelines and long-term treatment outcome studies in breast cancer and related oncological fields.

Best Publications

  • Impact of a Higher Radiation Dose on Local Control and Survival in Breast-Conserving Therapy of Early Breast Cancer: 10-Year Results of the Randomized Boost Versus No Boost EORTC 22881-10882 Trial

    Harry Bartelink;Jean-Claude Horiot;Philip M. Poortmans;Henk Struikmans

  • Duration of androgen suppression in the treatment of prostate cancer.

    Michel Bolla;Theodorus M. de Reijke;Geertjan Van Tienhoven;Alphonsus C.M. Van den Bergh

  • Regional Nodal Irradiation in Early-Stage Breast Cancer

    Timothy J. Whelan;Ivo A. Olivotto;Wendy R. Parulekar;Ida Ackerman

  • Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation.

    Harry Bartelink;Jean-Claude Horiot;Philip Poortmans;Henk Struikmans

  • Internal mammary and medial supraclavicular irradiation in breast cancer

    P.M.P. Poortmans;S. Collette;C. Kirkove;E. van Limbergen

  • Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma

    Lauren E. Abrey;Tracy T. Batchelor;Andrés J.M. Ferreri;Mary Gospodarowicz

  • Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

    Bernard Asselain;William Barlow;John Bartlett;Jonas Bergh

  • Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial

    Harry Bartelink;Philippe Maingon;Philip Poortmans;Caroline Weltens

  • Second Cancer Risk Up to 40 Years after Treatment for Hodgkin’s Lymphoma

    Michael Schaapveld;Berthe M.P. Aleman;Anna M. van Eggermond;Cécile P.M. Janus

  • Estimating the Benefits of Therapy for Early Stage Breast Cancer The St Gallen International Consensus Guidelines for the Primary Therapy of Early Breast Cancer 2019

    H.J. Burstein;G. Curigliano;S. Loibl;P. Dubsky

  • Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021.

    H J Burstein;G Curigliano;B Thürlimann;W P Weber

  • ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer.

    Birgitte V. Offersen;Liesbeth J. Boersma;Carine Kirkove;Sandra Hol

  • Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease

    Christophe Fermé;Houchingue Eghbali;Jacobus H. Meerwaldt;Chantal Rieux

  • The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC 'boost vs. no boost' trial

    Conny Vrieling;Laurence Collette;Alain Fourquet;Willem J. Hoogenraad

  • Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: Concepts and guidelines

    Theodore Girinsky;Richard van der Maazen;Lena Specht;Berthe Aleman

  • High-Dose Methotrexate-Based Chemotherapy Followed by Consolidating Radiotherapy in Non–AIDS-Related Primary Central Nervous System Lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962

    Philip M.P. Poortmans;Hanneke C. Kluin-Nelemans;Hanny Haaxma-Reiche;Mars Van’t Veer

  • Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

    Richard Gray;Rosie Bradley;Jeremy Braybrooke;Zulian Liu

  • Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group

    Philip Poortmans;Alberto Bossi;Katia Vandeputte;Mathieu Bosset

  • Regional Nodal Irradiation in Early-Stage Breast Cancer.

    Philip M Poortmans;Henk Struikmans;Harry Bartelink

  • O-113 Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the Randomized Boost Versus No Boost EORTC 22881–10882 Trial

    H. Struikmans;H. Bartelink;J.C. Horiot;P.M. Poortmans

Frequent Co-Authors

Harry Bartelink
Harry Bartelink Antoni van Leeuwenhoek Hospital
Alain Fourquet
Alain Fourquet Institute Curie
Laurence Collette
Laurence Collette European Organisation for Research and Treatment of Cancer
Fatima Cardoso
Fatima Cardoso Champalimaud Foundation
Dirk De Ruysscher
Dirk De Ruysscher Maastricht University
Giuseppe Curigliano
Giuseppe Curigliano University of Milan
John Yarnold
John Yarnold Institute of Cancer Research
Jan Willem Coebergh
Jan Willem Coebergh Erasmus University Rotterdam
Reshma Jagsi
Reshma Jagsi University of Michigan–Ann Arbor
Martine Piccart
Martine Piccart Université Libre de Bruxelles

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medical careers in the USA now includes more flexible and affordable options through online education. For aspiring nurses, finding the cheapest online dnp programs can help elevate your qualifications while balancing work and life commitments. Similarly, future pharmacists can pursue their passion through accredited online pharmacy school programs, which offer rigorous curriculums without the need to relocate.

Those interested in the administrative side of healthcare may consider degrees in Health Information Management. The best online schools for high school students also offer pathways into this growing field, enabling early exposure to medical technology and data management. Meanwhile, medical billing and coding continues to be in demand; obtaining a medical coding certification online provides a way to quickly launch a career supporting healthcare operations.

Online programs provide new opportunities for flexible learning, accessible credentials, and diverse pathways into the medical sector. Prospective students should research and compare programs to ensure they meet educational and career goals.

Best Scientists Citing Philip Poortmans

Trending Scientists

Recently Published Articles